Formulation Development
Cellectricon & StressMarq Biosciences Collaborate to Develop Next-Generation Reagents & Assays
Cellectricon recently announced a collaboration with StressMarq Biosciences. As a supplier of life science reagents such as primary antibodies, antibody conjugates, proteins, immunoassay kits and…
PharmaCyte Biotech Will Have All the Protection It Needs Upon Marketing Approval
PharmaCyte Biotech recently announced it is about to embark upon a planned US FDA Phase 2b clinical trial to treat locally advanced, inoperable pancreatic cancer (LAPC) at trial sites all over the US, and with that journey comes the….
Catalent to Acquire Leading Cell Therapy Company MaSTherCell Global
Catalent, Inc. recently announced it has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. for an aggregate of…..
Conatus Pharmaceuticals & Histogen Enter Definitive Merger Agreement
Conatus Pharmaceuticals Inc. and Histogen Inc. recently announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly owned subsidiary of….
Albireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases
Albireo Pharma, Inc. recently announced a number of advances and new initiatives in the clinical program for odevixibat, an oral once daily capsule in development for….
BioPharmX & Timber Pharmaceuticals Announce Merger Agreement
BioPharmX Corporation and Timber Pharmaceuticals LLC recently announced they have entered into a definitive merger agreement. Under the terms of the merger agreement, subject to the approval of…..
Ubiquigent Launches a New Service to Facilitate Target Validation of DUB Enzymes & Determine Compound-DUB Target Engagement & Selectivity of Novel Compounds in Cells
Ubiquigent Limited (Ubiquigent) recently announced the launch of an exciting new service as part of its Drug Discovery Screening Platform – DUBprofiler-Cell. DUBprofiler-Cell supports the…
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134
Rubius Therapeutics, Inc. recently announced that the first patient has been dosed in its Phase 1b trial of RTX-134, an allogeneic, off-the-shelf cellular therapy for…
Vetter Aligns its Development Service Laboratory Portfolio
Vetter, a global operating Contract Development and Manufacturing Organization (CDMO) has brought together its development laboratories in one Ravensburg site end of last year. Designed…
Avacta’s Proprietary TMAC Cancer Therapy Platform Demonstrates Successful Proof-of-Concept
Avacta Group plc recently announced it has demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, TMAC, in a preclinical animal model of…
Cabaletta Bio Receives Orphan Drug Designation for DSG3-CAART
Cabaletta Bio, Inc. recently announced that the US FDA has granted Orphan Drug Designation for the company’s lead product candidate, DSG3-CAART, for the treatment of…
Akcea & Ionis Report Positive Topline Phase 2 Study Results
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. recently announced positive topline results from the Phase 2 study of AKCEA-ANGPTL3-LRx in patients with hypertriglyceridemia, type 2…
Drug Developers Are Making Strides in Streamlining Patient Recruitment & Retention for Clinical Trials
Efforts by drug developers during the past decade to improve recruitment and retention of patients for clinical trials appear to be paying off, as enrollment…
GeoVax & BravoVax to Collaborate on Development of Coronavirus Vaccine
GeoVax Labs, Inc. and BravoVax recently announced the signing of a Letter of Intent to jointly develop a vaccine against the new coronavirus (known as…
Krystal Biotech Breaks Ground On Second Commercial Gene Therapy Manufacturing Facility
Krystal Biotech, Inc. recently announced the ground breaking of the second commercial gene therapy facility in Findlay Township, PA. The Findlay-based Current Good Manufacturing Practice…
Catalent Biologics Supports DiaMedica's New Treatment
Catalent recently welcomed the news that DiaMedica Therapeutics has received US FDA approval to commence Phase 2 clinical trials of its lead candidate, DM199, for…
Ritter Pharmaceuticals & Qualigen Announce Merger Agreement
Ritter Pharmaceuticals, Inc. recently reported it has entered into a definitive reverse merger agreement with Qualigen, Inc. as well as expansion of its flagship FastPack diagnostic platform, whereby a wholly owned…..
TEDOR Pharma Adds Frank Sorce as Regional Business Development Director
TEDOR Pharma, a Contract Development and Manufacturing Organization with a 19-year operating history, is pleased to announce Frank Sorce is joining TEDOR as the new…..
Interpace Biosciences Enters Agreement for $20-Million Investment
Interpace Biosciences, Inc. recently announced that it has entered into an agreement for a new Series B Preferred Stock investment of….
Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease
Biogen Inc. recently announced an agreement to acquire from Pfizer Inc. a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with…
